Senzimes first day of trading on Nasdaq First North

Uppsala, April 11, 2017. Senzime AB (publ) recently completed a rights issue that raised SEK 24.4 million before issue costs. Senzime has applied for listing on Nasdaq First North which has been approved with first day of trading April 11, 2017. Previously Senzime was listed on AktieTorget.

"With the recently completed financing, we can accelerate the commercialization and take aim at further licensing and distribution agreements as a follow up to the agreements we have already signed in Japan, Australia, New Zealand, Ireland and England. In connection with this, we have chosen to list Senzimes shares on Nasdaq First North to receive more visibility on the stock market and also enable broader institutional ownership in the company, "says Lena Söderström, CEO of Senzime.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: 


About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). 

Explore our patient monitoring solutions

Get product details

How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.